GenMark Diagnostics, Inc (NASDAQ:GNMK) SVP Michael Gleeson sold 1,916 shares of the firm’s stock in a transaction dated Friday, May 19th. The shares were sold at an average price of $12.89, for a total value of $24,697.24. Following the transaction, the senior vice president now directly owns 293,922 shares of the company’s stock, valued at approximately $3,788,654.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Michael Gleeson also recently made the following trade(s):

  • On Friday, March 3rd, Michael Gleeson sold 353 shares of GenMark Diagnostics stock. The shares were sold at an average price of $12.29, for a total value of $4,338.37.

GenMark Diagnostics, Inc (NASDAQ:GNMK) traded down 0.83% during trading on Tuesday, hitting $13.10. The company had a trading volume of 107,956 shares. The firm has a 50-day moving average of $12.96 and a 200 day moving average of $12.25. The company’s market capitalization is $616.84 million. GenMark Diagnostics, Inc has a 12-month low of $6.65 and a 12-month high of $13.67.

GenMark Diagnostics (NASDAQ:GNMK) last released its quarterly earnings data on Tuesday, May 2nd. The medical equipment provider reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by $0.02. The company had revenue of $12.54 million during the quarter, compared to the consensus estimate of $12.55 million. GenMark Diagnostics had a negative net margin of 98.17% and a negative return on equity of 114.35%. On average, equities research analysts forecast that GenMark Diagnostics, Inc will post ($0.96) earnings per share for the current year.

Insider Buying and Selling by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

TRADEMARK VIOLATION NOTICE: “Michael Gleeson Sells 1,916 Shares of GenMark Diagnostics, Inc (GNMK) Stock” was first published by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/05/23/michael-gleeson-sells-1916-shares-of-genmark-diagnostics-inc-gnmk-stock.html.

GNMK has been the subject of several research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $15.00 target price on shares of GenMark Diagnostics in a research note on Wednesday, March 1st. BTIG Research reaffirmed a “buy” rating and set a $17.00 target price on shares of GenMark Diagnostics in a research note on Wednesday, May 17th. Zacks Investment Research raised GenMark Diagnostics from a “sell” rating to a “hold” rating in a research note on Friday, March 3rd. Finally, Canaccord Genuity set a $14.00 target price on GenMark Diagnostics and gave the company a “buy” rating in a research note on Monday, January 23rd. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. GenMark Diagnostics presently has a consensus rating of “Buy” and an average price target of $15.17.

A number of large investors have recently added to or reduced their stakes in GNMK. Guggenheim Capital LLC increased its stake in GenMark Diagnostics by 0.4% in the fourth quarter. Guggenheim Capital LLC now owns 10,694 shares of the medical equipment provider’s stock worth $131,000 after buying an additional 39 shares in the last quarter. Nationwide Fund Advisors increased its stake in GenMark Diagnostics by 3.9% in the first quarter. Nationwide Fund Advisors now owns 25,936 shares of the medical equipment provider’s stock worth $332,000 after buying an additional 981 shares in the last quarter. American International Group Inc. increased its stake in GenMark Diagnostics by 7.8% in the first quarter. American International Group Inc. now owns 24,885 shares of the medical equipment provider’s stock worth $319,000 after buying an additional 1,802 shares in the last quarter. Metropolitan Life Insurance Co. NY increased its stake in GenMark Diagnostics by 10.2% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 29,013 shares of the medical equipment provider’s stock worth $355,000 after buying an additional 2,689 shares in the last quarter. Finally, TD Asset Management Inc. increased its stake in GenMark Diagnostics by 3.1% in the first quarter. TD Asset Management Inc. now owns 102,074 shares of the medical equipment provider’s stock worth $1,309,000 after buying an additional 3,074 shares in the last quarter.

GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.

12 Month Chart for NASDAQ:GNMK

Receive News & Ratings for GenMark Diagnostics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics Inc and related companies with MarketBeat.com's FREE daily email newsletter.